Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Julphar
US Department of Justice
Cerilliant
Harvard Business School
McKinsey
McKesson
Cipla
Daiichi Sankyo
Baxter
US Army

Generated: February 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019678

« Back to Dashboard

NDA 019678 describes ENLON-PLUS, which is a drug marketed by Mylan Institutional and is included in two NDAs. Additional details are available on the ENLON-PLUS profile page.

The generic ingredient in ENLON-PLUS is atropine sulfate; edrophonium chloride. There are twenty-three drug master file entries for this compound. Additional details are available on the atropine sulfate; edrophonium chloride profile page.
Summary for 019678
Tradename:ENLON-PLUS
Applicant:Mylan Institutional
Ingredient:atropine sulfate; edrophonium chloride
Patents:0
Formulation / Manufacturing:see details

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength0.14MG/ML;10MG/ML
Approval Date:Nov 6, 1991TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Fish and Richardson
Cerilliant
Chubb
Daiichi Sankyo
Merck
Healthtrust
Cantor Fitzgerald
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot